Myeloid differentiation protein 2 induced retinal ischemia reperfusion injury via upregulation of ROS through a TLR4-NOX4 pathway. (5th January 2018)
- Record Type:
- Journal Article
- Title:
- Myeloid differentiation protein 2 induced retinal ischemia reperfusion injury via upregulation of ROS through a TLR4-NOX4 pathway. (5th January 2018)
- Main Title:
- Myeloid differentiation protein 2 induced retinal ischemia reperfusion injury via upregulation of ROS through a TLR4-NOX4 pathway
- Authors:
- Chen, Huaicheng
Song, Zongming
Ying, Shilong
Yang, Xi
Wu, Wei
Tan, Qiufan
Ju, Xin
Wu, Wencan
Zhang, Xin
Qu, Jia
Wang, Yi - Abstract:
- Highlights: ROS is a key pathological event in retinal I/R injury. MD2/TLR4 signaling pathway is involved in oxidative damage in the retina I/R. MD2 is required for the formation of TLR4/NOX4 complex. Targeting MD2 is a potential therapeutic approach in various ophthalmic diseases. Abstract: Retinal ischemia reperfusion (I/R) injury is common in many ophthalmic diseases. Recent studies have shown that toll-like receptor 4 (TLR4) is involved in ischemic retinal injury. Activation of TLRs requires specific accessory proteins such as myeloid differentiation protein 2 (MD2), which facilitate in ligand responsiveness. Therefore, inhibiting MD2 may be a novel approach to modulate TLR4 signaling and deleterious downstream effects in ischemic retinal injury. We used human Müller MIO-M1 cells treated with tert-butyl hydroperoxide (TBHP) to establish an in vitro I/R model of oxidative injury and tested the therapeutic effect of inhibiting MD2. Furthermore, we inhibited MD2 in a mouse model of retinal I/R injury and confirmed the results using MD2 knockout mice. Our studies show that pharmacological inhibition of MD2 prevented TBHP-induced reactive oxygen species (ROS) generation, inflammation and subsequent apoptosis in Müller cells. We also show that retinal I/R injury in mice induced functional deficits, increased ROS levels, inflammation and apoptosis. These pathological changes were not observed in MD2 knockout mice and attenuated when MD2 was inhibited in wildtype mice. InHighlights: ROS is a key pathological event in retinal I/R injury. MD2/TLR4 signaling pathway is involved in oxidative damage in the retina I/R. MD2 is required for the formation of TLR4/NOX4 complex. Targeting MD2 is a potential therapeutic approach in various ophthalmic diseases. Abstract: Retinal ischemia reperfusion (I/R) injury is common in many ophthalmic diseases. Recent studies have shown that toll-like receptor 4 (TLR4) is involved in ischemic retinal injury. Activation of TLRs requires specific accessory proteins such as myeloid differentiation protein 2 (MD2), which facilitate in ligand responsiveness. Therefore, inhibiting MD2 may be a novel approach to modulate TLR4 signaling and deleterious downstream effects in ischemic retinal injury. We used human Müller MIO-M1 cells treated with tert-butyl hydroperoxide (TBHP) to establish an in vitro I/R model of oxidative injury and tested the therapeutic effect of inhibiting MD2. Furthermore, we inhibited MD2 in a mouse model of retinal I/R injury and confirmed the results using MD2 knockout mice. Our studies show that pharmacological inhibition of MD2 prevented TBHP-induced reactive oxygen species (ROS) generation, inflammation and subsequent apoptosis in Müller cells. We also show that retinal I/R injury in mice induced functional deficits, increased ROS levels, inflammation and apoptosis. These pathological changes were not observed in MD2 knockout mice and attenuated when MD2 was inhibited in wildtype mice. In addition, we discovered that the mechanism of these therapeutic effects involved regulation of NADPH oxidase 4 (NOX4)-MD2-TLR4 complex formation. This study provides evidence that MD2 plays a key role in the pathogenesis of retinal I/R damage by participating in TLR4-NOX4 complex formation and elaboration of oxidative and inflammatory damage. Hence, inhibition of MD2 may reduce TLR-dependent damage during retinal I/R injury. … (more)
- Is Part Of:
- Toxicology letters. Volume 282(2018)
- Journal:
- Toxicology letters
- Issue:
- Volume 282(2018)
- Issue Display:
- Volume 282, Issue 2018 (2018)
- Year:
- 2018
- Volume:
- 282
- Issue:
- 2018
- Issue Sort Value:
- 2018-0282-2018-0000
- Page Start:
- 109
- Page End:
- 120
- Publication Date:
- 2018-01-05
- Subjects:
- MD2 -- TLR4 -- HMGB1 -- NOX4 -- Retinal ischemia-reperfusion injury
Toxicology -- Periodicals
363.179 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03784274 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.toxlet.2017.10.018 ↗
- Languages:
- English
- ISSNs:
- 0378-4274
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8873.042000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 5321.xml